Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Acceleron Pharma (XLRN)

120.95   -4.93 (-3.92%) 01-27 02:43
Open: 125.43 Pre. Close: 125.88
High: 126.635 Low: 120.0026
Volume: 228,672 Market Cap: 7,287M
Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 126.998 - 127.702 127.702 - 128.274
Low: 117.884 - 118.853 118.853 - 119.64
Close: 119.523 - 120.962 120.962 - 122.132

Technical analysis

as of: 2021-01-26 4:50:37 PM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 148.77     One year: 159.14
Support: Support1: 113.01    Support2: 94.02
Resistance: Resistance1: 127.37    Resistance2: 136.25
Pivot: 123.30
Moving Average: MA(5): 124.51     MA(20): 124.09
MA(100): 115.00     MA(250): 102.70
MACD: MACD(12,26): 0.31     Signal(9): 0.60
Stochastic oscillator: %K(14,3): 53.40     %D(3): 57.79
RSI: RSI(14): 45.20
52-week: High: 136.25  Low: 66.44  Change(%): 51.6
Average Vol(K): 3-Month: 31066  10-Days: 33710

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
XLRN has closed above bottom band by 35.7%. Bollinger Bands are 5.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Mon, 25 Jan 2021
Acceleron Pharma Inc. (XLRN) Soars 1.03% on January 25 -

Mon, 25 Jan 2021
Acceleron Pharma Inc. (NASDAQ:XLRN) Given Consensus Rating of "Buy" by Analysts - MarketBeat

Tue, 19 Jan 2021
Acceleron Pharma Inc. (XLRN) Soars 4.98% on January 19 -

Tue, 19 Jan 2021
Raymond James Boosts Acceleron Pharma (NASDAQ:XLRN) Price Target to $160.00 - MarketBeat

Tue, 19 Jan 2021
Analysts’ Top Healthcare Picks: Acceleron Pharma (XLRN), Zymeworks (ZYME) - Smarter Analyst

Fri, 15 Jan 2021
Noteworthy Friday Option Activity: PATK, XLRN, NET - Nasdaq

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Neutral Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 60
Shares Float (M) 53
% Held by Insiders 12.18
% Held by Institutions 90.06
Shares Short (K) 2,930
Shares Short P. Month (K) 3,510

Stock Financials

EPS -2.400
EPS Est This Year -2.690
EPS Est Next Year -2.280
Book Value (p.s.) 14.910
Profit Margin -124.73
Operating Margin -127.64
Return on Assets (ttm) -11.5
Return on Equity (ttm) -19.4
Qtrly Rev. Growth 436.1
Gross Profit (p.s.) -1.327
Sales Per Share 1.759
EBITDA (p.s.) -2.182
Qtrly Earnings Growth
Operating Cash Flow (M) -108
Levered Free Cash Flow (M) -67

Stock Valuations

PE Ratio -50.40
PEG Ratio
Price to Book value 8.11
Price to Sales 68.75
Price to Cash Flow -67.19

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.